Therapeutics News and Research

RSS

The CMS demonstration project in oncology

The PricewaterhouseCoopers study that the Community Oncology Alliance (COA) commissioned shows that an estimated $13 billion will be saved from Medicare spending for cancer care through 2013. This is $8.8 billion more than the original intent of Congress in passing the Medicare Modernization Act (MMA).

22 Jun 2005

Rosetta Genomics identifies hundreds of novel human microRNAs

In a study published online this week and to be published as a cover story in the July issue of Nature Genetics, Rosetta Genomics' scientists report identification of hundreds of human microRNA genes, including the first report of primate specific microRNAs.

21 Jun 2005

Columbia University launches multi-year campaign to support stem cell researc

Columbia University Medical Center (CUMC) has announced that it is halfway toward realizing the first phase of a multi-year campaign to build upon the university’s groundbreaking stem cell research and lead the effort to fully realize the therapeutic potential of stem cells.

16 Jun 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

Nanotechnology used to smuggle a powerful chemotherapeutic drug inside tumor cells

University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells - increasing the drug's cancer-killing activity and reducing its toxic side effects.

15 Jun 2005

Chemokine Therapeutics granted new U.S patent

Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.

14 Jun 2005

Designed drug for combined hormone and chemotherapy treatment

The search for new drugs to fight cancer remains at the top of the to do list for pharmaceutical researchers. A recent variation is polymer chemotherapy agents, drugs that have been attached to a "backbone" of long chain molecules.

9 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Virulizin granted orphan drug status in Europe

Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.

8 Jun 2005

Researchers successfully image delivery and gene expression of DNA nanoparticles into lungs of CF mice

Researchers at the American Society of Gene Therapy Meeting in St. Louis announced that by using imaging technologies, they are able to successfully trace the delivery of DNA nanoparticles and the extent of gene transfer in the lungs of cystic fibrosis (CF) animals.

6 Jun 2005

Introgen wins European patent decision on p53 gene therapeutic

Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the EPO's Technical Board of Appeals.

3 Jun 2005

Newly discovered gene could provide targets for diabetes therapies

The Juvenile Diabetes Research Foundation (JDRF) has announced that JDRF-funded researchers in Australia and the United Kingdom have identified a gene called Roquin that regulates the immune system and keeps harmful T cells in check.

1 Jun 2005

Nastech Pharmaceutical awarded new breast cancer patent

Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."

31 May 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

Protein, called "eed," crucial to the regulation of genes in embryonic stem cells

New research from University of North Carolina at Chapel Hill shows how a protein may be crucial to the regulation of genes in embryonic stem cells.

26 May 2005

Study shows how COX-2 inhibitors lead to heart disease

University of Pennsylvania School of Medicine researchers have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and stroke.

26 May 2005

Anti-inflammatory protein annexin 1 may protect patients from the detrimental effects of severe inflammatory response syndrome

Severe inflammatory response syndrome, or SIRS, occurs when the body's response to an overwhelming infection becomes uncontrolled. The very immune response meant to clear the pathogen and its toxins actually causes damage to the host's own tissues when it goes into overdrive, releasing too many immune signals.

23 May 2005

Market forces alone are not sufficient to produce new drugs needed for children with cancer

Faced with "a near absence of research in pediatric cancer drug discovery," the IOM report recommends forming new public-private partnerships among government, industry, researchers, advocacy groups and other parties to lead research and development.

23 May 2005

Researchers find first gene for inherited testicular cancer in mice

In this week's journal Nature, researchers report finding the first gene responsible for inherited susceptibility of testicular cancer in mice. The Ter mutation occurs in a gene called dead end, which is involved in normal testicular development and which may play a role in inherited forms of a testicular cancer occurring in infants.

20 May 2005

Tumor vasculature has become an attractive target in the treatment of cancer.

Treatment with a protein fused to an antibody in tumor-bearing mice led to coagulation of the blood within the tumor blood vessels, tumor tissue death, and tumor growth delay, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.

17 May 2005